Considering its properties of not only suppressing Mcl-1 but also upregulate BH3-only proteins, TPL with a broader antileukemia spectrum might thus represent an optimal agent to potentiate antitumor activity of ABT-199 in AML. The gene discussed is MCL1; the disease is acute myeloid leukemia.